Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Yu, Jian  [Clear All Filters]
2013
Yu J. Intestinal stem cell injury and protection during cancer therapy. Transl Cancer Res. 2013;2(5):384-396.
2014
Wu X, Du Z, Yu J, Sun Y, Pei B, Lu X, Tang Z, Yin M, Zhou L, Hu J. Activity of factor VII in patients with isolated blunt traumatic brain injury: Association with coagulopathy and progressive hemorrhagic injury. J Trauma Acute Care Surg. 2014;76(1):114-20.
2016
Zhu N, Wang H, Wei J, Wang B, Shan W, Lai X, Zhao Y, Yu J, Huang H. NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells. Mol Med Rep. 2016.
2018
Zhu Y, Li X, Janairo RRaphael R, Kwong G, Tsou AD, Chu JS, Wang A, Yu J, Wang D, Li S. Matrix stiffness modulates the differentiation of neural crest stem cells in vivo. J Cell Physiol. 2018.
Bodak M, Yu J, Ciaudo C. Regulation of LINE-1 Elements by miR-128 Is Not Conserved in Mouse Embryonic Stem Cells. Front Genet. 2018;9:683.
2019
Gao F, Shi J, Luo Y, Tan Y, Lai X, Yu J, Huang H, Zhao Y. The incidence, Risk factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Yu C, Liu Q, Chen C, Yu J, Wang J. Landscape perspectives of tumor, EMT, and development. Phys Biol. 2019.
2020
Zhao Y, Shi J, Luo Y, Gao F, Tan Y, Lai X, Yu J, Wei G, Huang H. Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2020.
Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, et al. Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Wu Y, Shi J, Tan Y, Zhao Y, Yu J, Lai X, Yang L, Huang H, Luo Y. A novel strategy for the prevention of HBV-related hepatitis following allogeneic hematopoietic stem cell transplantation from HBsAg-positive donors lantation from HBsAg-positive donors. Biol Blood Marrow Transplant. 2020.
2021
Fan T, He J, Wang Y, Yu J, Sun W. Generation of an induced pluripotent stem cell line (FDCHi006-A) from a 7-year-old girl with central precocious puberty. Stem Cell Res. 2021;56:102542.
2022
Yang T-T, Song X-L, Zhao Y-M, Ye B-D, Luo Y, Xiao H-W, Chen Y, Fu H-R, Yu J, Liu L-Z, et al. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. Ann Hematol. 2022.
2023
Qu J, Wang X, Zhang Y, Hu R, Hao Y, Zhao X, Dong C, Yang C, Zhang W, Sui J, et al. Cell reprogramming in a predictable manner on the superhydrophobic microwell array chip. Biomaterials. 2023;301:122215.
Yang T, Jiang B, Luo Y, Zhao Y, Ouyang G, Yu J, Lan J, Lu Y, Lai X, Ye B, et al. Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms. Am J Hematol. 2023.
Zhou L, Fu W, Wu S, Xu K, Qiu L, Xu Y, Yan X, Zhang Q, Zhang M, Wang L, et al. Derivation and validation of a novel score for early prediction of severe CRS after CAR-T therapy in haematological malignancy patients: A multi-centre study. Br J Haematol. 2023.
Gao F, Shi Z, Shi J, Luo Y, Yu J, Fu H, Lai X, Liu L, Yuan Z, Zheng Z, et al. Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation. HLA. 2023.
Liu L, Ji X, Zhu P, Yang L, Shi J, Zhao Y, Lai X, Yu J, Fu H, Ye Y, et al. Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023.
Wu H, Zhao Y, Gao F, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Qian P, et al. Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis. J Transl Med. 2023;21(1):329.
Xu X, Zu C, Zhang M, Xiao P, Hong R, Feng J, Xu H, Cui J, Yu J, Shi J, et al. HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma. Cell Transplant. 2023;32:9636897231194265.
Yuan X-L, Lai X-Y, Wu Y-B, Yang L-X, Shi J-M, Liu L-Z, Yu J, Zhao Y-M, Zheng W-Y, He J-S, et al. A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation. Bone Marrow Transplant. 2023.
Gao Y, Wu H, Shi Z, Gao F, Shi J, Luo Y, Yu J, Lai X, Fu H, Liu L, et al. Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Wu L, Wu Y, Shi J, Lai X, Zhao Y, Liu L, Yu J, Yang L, Zhu P, Zheng W, et al. Survival and late mortality among patients who survived disease-free for 2 years after stem cell transplantation. Br J Haematol. 2023.
2024
Du M, Wang M, Liu M, Fu S, Lin Y, Huo Y, Yu J, Yu X, Wang C, Xiao H, et al. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription. J Exp Clin Cancer Res. 2024;43(1):79.
Guan F, Yang L, Chen Y, Shi J, Song X, Lai X, Lu Y, Liu L, Ouyang G, Zhao Y, et al. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Cancer. 2024.
Chen W, Huang J, Zhao Y, Huang L, Yuan Z, Gu M, Xu X, Shi J, Luo Y, Yu J, et al. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study. J Transl Med. 2024;22(1):410.

Pages